US Bancorp
RLAY icon

US Bancorp’s Relay Therapeutics RLAY Stock Holding History

US Bancorp’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.4K Buy
5,258
+26
+0.5% +$377 ﹤0.01% 2465
2026
Q1 		$52.1K Buy
5,232
+101
+2% +$904 ﹤0.01% 2691
2025
Q4 		$43.4K Hold
5,131
– – ﹤0.01% 2758
2025
Q3 		$26.8K Sell
5,131
-354
-6% -$1.35K ﹤0.01% 2955
2025
Q2 		$19K Buy
5,485
+4,208
+330% +$12.5K ﹤0.01% 3188
2025
Q1 		$3.35K Sell
1,277
-2,534
-66% -$9.93K ﹤0.01% 3765
2024
Q4 		$15.7K Buy
3,811
+2,746
+258% +$14.9K ﹤0.01% 3256
2024
Q3 		$7.54K Sell
1,065
-840
-44% -$6.28K ﹤0.01% 3456
2024
Q2 		$12.4K Buy
1,905
+227
+14% +$1.55K ﹤0.01% 3237
2024
Q1 		$13.9K Sell
1,678
-150
-8% -$1.46K ﹤0.01% 3225
2023
Q4 		$20.1K Buy
+1,828
New +$15.4K ﹤0.01% 3051
2023
Q3 		– Sell
-129
Closed -$1.62K – 4094
2023
Q2 		$1.62K Buy
129
+93
+258% +$1.16K ﹤0.01% 3731
2023
Q1 		$593 Buy
+36
New +$646 ﹤0.01% 3932
2022
Q4 		– Sell
-266
Closed -$6K – 4262
2022
Q3 		$6K Buy
+266
New +$5.84K ﹤0.01% 3549
2022
Q2 		– Sell
-235
Closed -$7K – 4200
2022
Q1 		$7K Buy
+235
New +$5.7K ﹤0.01% 3518

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

US Bancorp's RLAY Position: Q2 2026 in Review

US Bancorp increased its Relay Therapeutics (RLAY) stake by 0.5% in Q2 2026, buying an estimated $377 and bringing the position to 5,258 shares worth $98.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2465.

US Bancorp first reported a position in RLAY in Q1 2022 and has held it in 15 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • US Bancorp held 5,258 shares of Relay Therapeutics worth $98.4K as of Q2 2026.
  • US Bancorp bought 26 Relay Therapeutics shares in Q2 2026, an estimated $377.
  • Relay Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2465 holding.
  • US Bancorp first reported a position in Relay Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.